Fecal Immunogenic Peptide Detection for Celiac Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and reliable way to monitor compliance with a gluten-free diet in celiac disease patients, particularly for detecting minor dietary transgressions and involuntary gluten exposure, which can lead to persistent symptoms and refractory celiac disease.
Innovation Solution
The use of immunological methods involving antibodies that recognize immunogenic peptides resistant to gastrointestinal digestion, such as the 33-mer peptide from gliadin, for detecting gluten peptides in fecal samples through techniques like ELISAs and immunochromatographic assays, allowing for quantitative and qualitative analysis of gluten intake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dietary monitoring methods (patient interviews, dietary records) are used, then compliance assessment is simple and non-invasive, but they lack reliability and cannot detect minor dietary transgressions or involuntary gluten exposure
Solution Approach 1:
The patent uses fecal samples as an intermediary medium to indirectly detect gluten ingestion. Instead of directly measuring gluten in the body or relying on patient reports, the method measures immunogenic gluten peptides excreted in feces, which serve as objective biomarkers of dietary compliance and refractory celiac disease status
Solution Approach 2:
The patent replaces subjective patient reporting systems with objective immunological measurement systems. By substituting patient interviews and dietary records with laboratory-based ELISA or immunochromatographic assays that detect specific gluten peptides in feces, the method eliminates human error, bias, and inability to detect minor exposures
2Measurement precision
If intestinal biopsies are performed to detect dietary transgressions, then diagnostic accuracy is high, but the procedure is invasive and requires anesthesia with potential complications
Solution Approach 1:
The patent extracts the diagnostic function from the invasive intestinal biopsy procedure and relocates it to a non-invasive fecal sample analysis. By measuring immunogenic gluten peptides in easily collected feces rather than performing surgical biopsies, the method achieves comparable diagnostic precision without the harmful effects of anesthesia, surgery, and procedural complications
Solution Approach 2:
The patent uses fecal immunogenic gluten peptides as an intermediary biomarker that reflects intestinal status without requiring direct intestinal sampling. These peptides serve as a surrogate marker that can be measured in accessible fecal samples, providing the same diagnostic information as biopsies but through a non-invasive route
3Reliability
If strict gluten-free diet compliance is monitored to prevent cumulative damage, then patient health outcomes improve, but current methods cannot reliably detect minor transgressions that lead to refractory celiac disease
Solution Approach 1:
The patent targets specific local characteristics of gluten peptides - the immunogenic 33-mer peptide from alpha-gliadin and related sequences - that are resistant to gastrointestinal digestion and remain detectable in feces. By focusing on these specific peptide sequences with known immunogenicity and resistance to proteolysis, the method can detect even minor gluten exposures that would be missed by general gluten detection methods
Solution Approach 2:
The patent changes the detection parameter from general gluten presence to specific immunogenic peptide levels in feces. By measuring the concentration of deamidated gluten peptides that are resistant to digestion and retain immunogenicity, the method achieves sensitive detection of minor transgressions, with the ability to quantify even low-level exposures that contribute to refractory celiac disease
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a sensitive and reliable method to monitor gluten ingestion, enabling early detection of dietary non-compliance and assessing the effectiveness of gluten detoxification therapies, thereby improving patient management and diagnosis of refractory celiac disease.
Implementation Method 1
The use of immunological methods involving antibodies that recognize immunogenic peptides resistant to gastrointestinal digestion, such as the 33-mer peptide from gliadin, for detecting gluten peptides in fecal samples
Implementation Method 2
techniques like ELISAs and immunochromatographic assays, allowing for quantitative and qualitative analysis of gluten intake
Implementation Method 3
techniques like ELISAs and immunochromatographic assays, allowing for quantitative and qualitative analysis of gluten intake
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3D
AI summary
The present invention relates to the medical/clinical sector and discloses a method for monitoring gluten ingestion by means of the measurement of gluten proteins/peptides in faeces using antibodies to immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is monitored by means of immunological assays based on antibodies that react with immunogenic gluten peptides that are proteolysis-resistant. Said assays may be quantitative ELISA techniques, or qualitative assays such as rapid immunochromatographic assays, immunoblots, etc.; These measurements could also be used to verify adherence to a gluten-free diet with a view to enhancing diagnosis in cases of refractory or acute symptoms of coeliac disease in cases where a gluten-free diet is allegedly being complied with, or in the clinical investigation of the effectiveness of prolamine detoxification-related enzyme therapies..